Drug development is complex, time consuming, and costly, and there is no guarantee that the drug candidate will make it through the process to commercialization.

7investing Lead Advisor Dana Abramovitz’s recommendation for August 2022 is a relatively young company that is disrupting drug development and working to create a new and growing market for therapeutics. The company already has three therapeutics on the market and has over a dozen more in its development pipeline. It saw triple digit growth YoY and is setting itself up to continue that growth as the market evolves.

Transcript

The health care industry is hard to disrupt. Medical schools care out the same traditions they’ve been using for hundreds of years, doctors use the same instruments, and the industry just seems resistant to change.

Hi, I’m Dana Abramovitz, 7investing Lead Advisor. We’re here to empower you to invest in your future by giving you our seven best stock recommendations every month.

My recommendation this month is a health technology company that is working to disrupt the health care industry and is actually succeeding. It is a first mover in a new and growing market and has multiple therapies on the market with a dozen more in its pipeline. It has seen triple digit growth year over year and it is setting itself up to continue growing.

To learn more about all seven stock recommendations this month, including mine, please visit 7investing.com/subscribe or click the link at the end of this video. We’re 7investing. We’re here to empower you to invest in your future.

Already a 7investing member? Log in here.